---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-22-000029"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2022-02-04T23:59:59+00:00"
generated_at: "2026-06-27T11:10:00.066972+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Immunovant Q3 net loss widens to $41.4M; cash at $527M; clinical pause continues

## Summary
- Net loss of $41.4M ($0.36 per share) for Dec 2021 quarter vs. $31.8M ($0.32) a year ago.
- R&D expenses rose to $29.8M from $21.1M, driven by clinical study costs and manufacturing.
- Cash and equivalents of $527.0M as of Dec 31, 2021; no revenue reported.
- G&A expenses increased to $11.5M from $10.5M year-over-year, partly due to stock-based compensation.
- Clinical trial activities remain paused due to previously announced voluntary hold.

## SEC filing metadata
- accession: 0001764013-22-000029
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2022-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000029/0001764013-22-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000029/imvt-20220204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-22-000029
- JSON: https://secwatch.observer/filing/0001764013-22-000029.json
- Plain text: https://secwatch.observer/filing/0001764013-22-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.